/PRNewswire/ - MYND Diagnostics Inc., a wholly-owned subsidiary of MYND Life Sciences (CSE: MYND) (OTC: MYNDF) is pleased to announce that the Company s.
Share on Twitter
In the comfort of his own home, Aaron Grinter is administering a new treatment that could change his life.
The 30-year-old has battled depression for more than 10 years and has taken the first steps to improve his mental health.
He is participating in a trial that uses electricity to increase the activity of neurons in his brain. This treatment seems different because it s not any of the things that are available at the moment, and it s non-invasive, Aaron said.
The practice is called Transcranial Alternating Current Stimulation (tACS) and it is part of a trial run by Paul Fitzgerald at the Epworth Centre for Innovation and Mental Health.